TG Therapeutics, INC.: directors' dealings · United States · SEC (Form 4)

About TG Therapeutics, INC.

TG Therapeutics, Inc. (ticker: TGTX) is a U.S.-based biopharmaceutical company listed on NASDAQ in the United States. The company is best understood as a specialty pharma / commercial biotech focused on B-cell–mediated diseases, with its strategic center of gravity in relapsing forms of multiple sclerosis. TG Therapeutics was founded in 1993, originally incorporated as Atlantic Pharmaceuticals, Inc., and its executive offices are in New York City, giving it a clear U.S. capital-markets profile. ([ir.tgtherapeutics.com](https://ir.tgtherapeutics.com/index.php/static-files/d48d6e88-4512-43c0-be01-f8c7d04c6719?utm_source=openai)) The company’s lead asset is BRIUMVI® (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved for adults with relapsing forms of multiple sclerosis. BRIUMVI is the main commercial driver of the business and the key asset supporting TG Therapeutics’ transition from development story to revenue-generating company. TG Therapeutics has also developed TGR-1202, an oral PI3K-delta inhibitor, although the investment case is primarily anchored in BRIUMVI commercialization and any potential lifecycle expansion programs. Recent company communications also highlight work on subcutaneous formulations and other pipeline opportunities, suggesting a broader effort to extend the product franchise over time. ([ir.tgtherapeutics.com](https://ir.tgtherapeutics.com/node/17521/pdf?utm_source=openai)) From a competitive standpoint, TG Therapeutics operates in a crowded MS treatment landscape dominated by large multinational pharmaceutical companies and established anti-CD20 therapies. Its differentiation depends on clinical profile, physician adoption, payer access, and execution in a market where neurologists have multiple treatment options. Because the company is relatively focused, the equity story is more concentrated than that of diversified pharma peers: upside is driven by commercial scaling, while downside sensitivity remains tied to regulatory execution, reimbursement, and competitive responses. That concentration increases risk, but it also gives investors a clearer line of sight into the core value driver. ([ir.tgtherapeutics.com](https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-commercial-launch-briumvitm?utm_source=openai)) Geographically, TG Therapeutics is primarily U.S.-focused, but it also has international exposure through ex-U.S. commercialization and partnerships for BRIUMVI in Europe and the United Kingdom. Recent disclosures show that the company reported $616.3 million of total revenue in 2025, including $594.1 million of U.S. net product revenue from BRIUMVI, and it guided 2026 total global revenue to approximately $875–900 million. For investors, that signals a business that has entered a more mature commercialization phase, even though execution risk, regulatory obligations, manufacturing reliance, and competitive pressure remain important considerations. ([ir.tgtherapeutics.com](https://ir.tgtherapeutics.com/press-releases?utm_source=openai))